AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2786735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh whole blood (2 units)
Number of subjects: 237
Study 2786735 — intervention group
Group type: COMPARATOR
Intervention: Stored blood (2-5 days)
Number of subjects: 237
Study 31859197 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesotherapy
Number of subjects: 0
Study 31859197 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexketoprofen (systemic therapy)
Number of subjects: 0
Study 31859197 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 30854836 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided implant surgery
Number of subjects: 7
Study 30854836 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 7
Study 29162181 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 0
Study 29162181 — intervention group
Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 0
Study 26716432 — intervention group
Group type: EXPERIMENTAL
Intervention: Icare tonometer (IT)
Number of subjects: 44
Study 23332456 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/day
Number of subjects: 336
Study 23332456 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH) 18, 36, or 54 mg/day
Number of subjects: 336
Study 23332456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 21654267 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 20 mg/d for 7 days
Number of subjects: 29
Study 18571625 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 25
Study 16827030 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartPrep
Number of subjects: 50
Study 16827030 — intervention group
Group type: COMPARATOR
Intervention: Conventional tungsten carbide bud bur
Number of subjects: 50
Study 15569270 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflaban (100 mg) suppository
Number of subjects: 20
Study 15569270 — intervention group
Group type: COMPARATOR
Intervention: Voltaren (100 mg) suppository
Number of subjects: 20
Study 10908215 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) 40 microg TID, n=209
Number of subjects: 549
Study 10908215 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=213
Number of subjects: 549
Study 9200380 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG-CSF (10 microg/kg/d x 3 d)
Number of subjects: 25
Study 9200380 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 25
Study 9200380 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG-CSF
Number of subjects: 25
Study 8295812 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (7.5 mg/kg twice daily for 7 to 10 days)
Number of subjects: 79
Study 8295812 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (20 mg/kg twice daily for 7 to 10 days)
Number of subjects: 79
Study 8295812 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 79
Study 8295812 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 79
Study 3307635 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ + PSK
Number of subjects: 0
Study 3307635 — intervention group
Group type: COMPARATOR
Intervention: CQ
Number of subjects: 0
Study 29438162 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum insulin (highest vs. lowest quartile)
Number of subjects: 21103
Study 29438162 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum glucose (highest vs. lowest quartile)
Number of subjects: 21103
Study 29438162 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum glucose and insulin
Number of subjects: 21103
Study 27840034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle joint mobilization
Number of subjects: 59
Study 27840034 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar massage
Number of subjects: 59
Study 27840034 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf stretching
Number of subjects: 59
Study 26117922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioxipin (10 mg/kg daily i/v droplet infusion)
Number of subjects: 56
Study 26117922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (10 ml in 200 ml 0.9% sodium chloride solution daily i/v droplet infusion for 10 days)
Number of subjects: 56
Study 26117922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment with cytoflavin and cardioxipin)
Number of subjects: 56
Study 23117749 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous electric nerve stimulation
Number of subjects: 37
Study 23117749 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 37
Study 23117749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 21738958 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen (LN)
Number of subjects: 16
Study 21738958 — intervention group
Group type: COMPARATOR
Intervention: Portable system (PS)
Number of subjects: 16
Study 18811802 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scan
Number of subjects: 37
Study 16563208 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated assessment (care management with additional clinical assessment by old age psychiatrist or geriatrician)
Number of subjects: 0
Study 16563208 — intervention group
Group type: COMPARATOR
Intervention: Care management assessment only
Number of subjects: 0
Study 14672354 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin treatment (not specified dosage or duration)
Number of subjects: 33
Study 14672354 — intervention group
Group type: COMPARATOR
Intervention: No calcitonin treatment (control group)
Number of subjects: 33
Study 10852316 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative NSAIDs (medium-to-high-dose regimens)
Number of subjects: 4129
Study 10852316 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 4129
Study 10852316 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID regimens
Number of subjects: 4129
Study 10852316 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 4129
Study 8603962 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 16
Study 8603962 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 16
Study 1349990 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based team (n = 48)
Number of subjects: 100
Study 1349990 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based service (n = 52)
Number of subjects: 100
Study 6329769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyphenonium bromide 3 X 10 mg
Number of subjects: 8
Study 6329769 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 3 X 5 mg
Number of subjects: 8
Study 6329769 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 2 X 300 mg
Number of subjects: 8
Study 6329769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31545671 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% prilocaine with 0.03 IU/mL felypressin (P + FP)
Number of subjects: 22
Study 31545671 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:80,000 adrenaline (L + AD)
Number of subjects: 22
Study 29723393 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib added to rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (BzR‐hyperCVAD)
Number of subjects: 95
Study 29723393 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib added to rituximab, high‐dose methotrexate, and high‐dose cytarabine (BzR‐MA)
Number of subjects: 95
Study 29723393 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not specified)
Number of subjects: 95
Study 26213242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Daily Occupational Performance (CO‐OP) intervention for 10 weeks
Number of subjects: 20
Study 26213242 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular activity for 10 weeks)
Number of subjects: 20
Study 24658945 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound combined with sonographically guided intratumoral ethanol injection (group H + A)
Number of subjects: 40
Study 24658945 — intervention group
Group type: COMPARATOR
Intervention: High-intensity focused ultrasound treatment (group H)
Number of subjects: 40
Study 23100167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) tablet of mitiglinide and metformin (10 mg/500 mg)
Number of subjects: 24
Study 23100167 — intervention group
Group type: COMPARATOR
Intervention: Individual formulations of mitiglinide and metformin
Number of subjects: 24
Study 23100167 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (FDC and individual formulations)
Number of subjects: 24
Study 20502695 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 (EXP)
Number of subjects: 18
Study 20502695 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 18
Study 20502695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 18
Study 18846346 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% carbomer gel
Number of subjects: 60
Study 18846346 — intervention group
Group type: COMPARATOR
Intervention: 1% carboxymethyl cellulose (CMC) containing artificial tears
Number of subjects: 60
Study 16195074 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative education programs, home visits from an outpatient team (SG)
Number of subjects: 50
Study 16195074 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation often augmented by a stay at a rehabilitation center (CG)
Number of subjects: 50
Study 12056535 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarf (Julphar, UAE)
Number of subjects: 28
Study 12056535 — intervention group
Group type: COMPARATOR
Intervention: Ciprobay (Bayer AG, Germany)
Number of subjects: 28
Study 10387505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multimedia intervention (computer-based soap opera and interactive 'info-mercials')
Number of subjects: 378
Study 10387505 — intervention group
Group type: COMPARATOR
Intervention: Both intervention and control groups
Number of subjects: 378
Study 8839230 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF 296 (0.1, 0.5, 1.0 microgram/kg/min)
Number of subjects: 20
Study 8839230 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF 296 (2.0, 4.0, 6.0 micrograms/kg/min)
Number of subjects: 20
Study 8839230 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF 296 (10, 20, 40, 80 micrograms/kg) by 1-min i.v. injection
Number of subjects: 20
Study 8839230 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF 296 (80 micrograms/kg)
Number of subjects: 20
Study 8839230 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF 296 (40 and 80 micrograms/kg)
Number of subjects: 20
Study 8839230 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF 296
Number of subjects: 20
Study 2202551 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (3.0 g/day)
Number of subjects: 19
Study 2202551 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated acetylsalicylic acid (3.0 g/day)
Number of subjects: 19
Study 7069216 — intervention group
Group type: EXPERIMENTAL
Intervention: epicutaneous methyl prednisolone (MP) at 10‐4 molar concentration
Number of subjects: 54
Study 7069216 — intervention group
Group type: EXPERIMENTAL
Intervention: epicutaneous methyl prednisolone (MP) at 10‐5 molar concentration
Number of subjects: 54
Study 7069216 — intervention group
Group type: EXPERIMENTAL
Intervention: epicutaneous methyl prednisolone (MP) at 10‐6 molar concentration
Number of subjects: 54
Study 31852438 — intervention group
Group type: EXPERIMENTAL
Intervention: CT guided TRFA (Xper CT and fluoroscopy)
Number of subjects: 78
Study 31852438 — intervention group
Group type: COMPARATOR
Intervention: Standard TRFA (fluoroscopy only)
Number of subjects: 78
Study 28338566 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.06 mg/kg)
Number of subjects: 24
Study 28338566 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 μg/kg)
Number of subjects: 24
Study 28338566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study 25834684 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual simulation examination format (n=18)
Number of subjects: 35
Study 25834684 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral examination format (n=17)
Number of subjects: 35
Study 24166470 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective stenosis repair (treatment group)
Number of subjects: 58
Study 24166470 — intervention group
Group type: COMPARATOR
Intervention: Stenosis correction according to guidelines (control group)
Number of subjects: 58
Study 21480257 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic adjuvant therapy
Number of subjects: 0
Study 21480257 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment and adjuvant radiotherapy
Number of subjects: 0
Study 19691794 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic pancreatic stenting followed by needle-knife fistulotomy
Number of subjects: 22
Study 19691794 — intervention group
Group type: COMPARATOR
Intervention: Standard methods of cannulation without pre-cutting methods
Number of subjects: 22
Study 17556697 — intervention group
Group type: COMPARATOR
Intervention: Calcium plus 1100 IU vitamin D3/d (Ca + D)
Number of subjects: 1179
Study 17556697 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone (Ca-only)
Number of subjects: 1179
Study 17556697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1179
Study 15579215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine administered by patch
Number of subjects: 119
Study 15579215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 11836042 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CA) 10 mg/day
Number of subjects: 336
Study 11836042 — intervention group
Group type: COMPARATOR
Intervention: Micronized progesterone (MP) 200 mg/day
Number of subjects: 336
Study 9888411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (7 g three times per day)
Number of subjects: 14
Study 9888411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7 g glycine three times per day)
Number of subjects: 14
Study 7675605 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes focused midway between the ball and their feet (5 cm closer to their feet)
Number of subjects: 48
Study 7675605 — intervention group
Group type: COMPARATOR
Intervention: Eyes positioned directly over the ball
Number of subjects: 48
Study 2130294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose acetate membrane
Number of subjects: 12
Study 2130294 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan membrane
Number of subjects: 12
Study 540461 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 540461 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 540461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31436371 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV-related liver failure (HEV-LF) patients
Number of subjects: 809
Study 31436371 — intervention group
Group type: COMPARATOR
Intervention: Patients with cirrhosis
Number of subjects: 809
Study 27649777 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 40
Study 27649777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25274015 — intervention group
Group type: EXPERIMENTAL
Intervention: myDIDeA (Internet-delivered dietary intervention)
Number of subjects: 66
Study 23799691 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (weight loss ≥ 5% and improved glucose tolerance)
Number of subjects: 3880
Study 21585330 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg of intravenous metoclopramide
Number of subjects: 93
Study 21585330 — intervention group
Group type: COMPARATOR
Intervention: 1 g of intravenous paracetamol
Number of subjects: 93
Study 19037910 — intervention group
Group type: EXPERIMENTAL
Intervention: General Nordic Questionnaire for Psychological and Social Factors at Work (QPS(Nordic))
Number of subjects: 3976
Study 17915794 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 585
Study 17915794 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 585
Study 17915794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 585
Study 14551632 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health educator visits over a 2-year period to counsel mothers
Number of subjects: 269
Study 14551632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dental health educator visits)
Number of subjects: 269
Study 11098022 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical epididymal sperm aspiration (MESA)
Number of subjects: 88
Study 11098022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI) with frozen-thawed epididymal spermatozoa
Number of subjects: 88
Study 9010920 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 0.125 nmol/kg
Number of subjects: 8
Study 9010920 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 0.25 nmol/kg
Number of subjects: 8
Study 9010920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1328367 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention with physical exercise and dietary regulation (HI-A group)
Number of subjects: 0
Study 1328367 — intervention group
Group type: COMPARATOR
Intervention: Passive follow-up (HI-P group)
Number of subjects: 0
Study 1328367 — intervention group
Group type: COMPARATOR
Intervention: Active intervention (NI-A group)
Number of subjects: 0
Study 1328367 — intervention group
Group type: COMPARATOR
Intervention: Active intervention (LI-A group)
Number of subjects: 0
Study 3907039 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine perfusion
Number of subjects: 29
Study 3907039 — intervention group
Group type: COMPARATOR
Intervention: Cold storage
Number of subjects: 29
Study 31475367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (0.42-2.09 mg/kg enterally) in cohort 1
Number of subjects: 34
Study 31475367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (0.125 or 0.25 mg/kg IV) in cohort 2
Number of subjects: 34
Study 31475367 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of fluconazole (n=4)
Number of subjects: 34
Study 31475367 — intervention group
Group type: EXPERIMENTAL
Intervention: IV doses of 0.125, 0.5 and 1 mg/kg every 8 hours (in absence of fluconazole)
Number of subjects: 34
Study 29489038 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention (deprexis)
Number of subjects: 1004
Study 29489038 — intervention group
Group type: COMPARATOR
Intervention: Control group (care as usual)
Number of subjects: 1004
Study 26702863 — intervention group
Group type: EXPERIMENTAL
Intervention: Chester step test (CST)
Number of subjects: 77
Study 26702863 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified incremental step test (MIST)
Number of subjects: 77
Study 26702863 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 77
Study 26702863 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy volunteers)
Number of subjects: 77
Study 24708672 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice team-supported self-managed exposure programme with cognitive behaviour therapy-oriented psychoeducation and instructions in four manual-based appointments, plus ten protocol-based telephone contacts for symptom monitoring.
Number of subjects: 444
Study 24708672 — intervention group
Group type: COMPARATOR
Intervention: Usual care from general practitioners.
Number of subjects: 444
Study 22339845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to increase parent knowledge and involvement in infant pain management
Number of subjects: 0
Study 20511029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Compression Device (SCD)
Number of subjects: 50
Study 20511029 — intervention group
Group type: COMPARATOR
Intervention: Control (no SCD)
Number of subjects: 50
Study 18484692 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 315
Study 18484692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 15897420 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure procedure (group A)
Number of subjects: 35
Study 15897420 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (group B)
Number of subjects: 35
Study 12821428 — intervention group
Group type: EXPERIMENTAL
Intervention: Group T (totally occluded LAD, retrograde filling)
Number of subjects: 20
Study 12821428 — intervention group
Group type: COMPARATOR
Intervention: Group C (critical stenosis, antegrade filling)
Number of subjects: 20
Study 12821428 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 10227007 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE) for 21 days
Number of subjects: 39
Study 10227007 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CEE for 21 days followed by 5 mg/day of medrogestone for 7 days
Number of subjects: 39
Study 10227007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 39
Study 8683427 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-play instructional set
Number of subjects: 90
Study 8683427 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-effort instructional set
Number of subjects: 90
Study 8683427 — intervention group
Group type: COMPARATOR
Intervention: Standardized instruction (control)
Number of subjects: 90
Study 1650303 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dentifrice formulations (specific formulations not detailed)
Number of subjects: 192
Study 1650303 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 192
Study 6821809 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (Burroughs-Wellcome)
Number of subjects: 116